ASCO Studies Assess Biosimilar Substitution, Adoption in Oncology Practices
June 16th 2022Abstracts from the American Society of Clinical Oncology (ASCO) annual meeting took a look at the impact biosimilar substitution and increased biosimilar adoption had on spending within practices participating in value-based payment models and the Oncology Care Model.
Contributor: To Try or Not to Try? That’s Not the Question—Phase 3 Trials of Biosimilars and Beyond
June 15th 2022Ivo Abraham, PhD, chief scientist of Matrix45 and a member of The Center for Biosimilars® Advisory Board, explores the complicated world of phase 3 trials for biosimilars to answer the question of whether they are truly needed for establishing biosimilar safety and efficacy.
Eye on Pharma: New Indication for Riabni, Organon and Henlius Partner on 2 Biosimilar Candidates
June 14th 2022The FDA granted a new indication for rheumatoid arthritis for Riabni, a rituximab biosimilar, and Organon and Shanghai Henlius Biotech entered into a licensing agreement for 2 oncology biosimilar candidates.
Similar Effectiveness, Safety of Biosimilar CT-P6 vs Reference Trastuzumab in Retrospective Study
June 13th 2022An analysis of retrospective data demonstrated comparable safety and efficacy profiles between CT-P6, a trastuzumab biosimilar, and Herceptin (reference trastuzumab) combined with chemotherapy and pertuzumab.
Ryan Haumschild, PharmD, Advises Practices, Health Systems to Prep for Interchangeable Biosimilars
June 5th 2022Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives an overview of what practices and health systems need to prepare for as more interchangeable biosimilars enter the US market.
Biosimilar Policy Roundup: May 2022
May 31st 2022May brought a number of biosimilar policy updates of all types, including updates on British Columbia's switching program, a new bill that could revamp biosimilar user fee programs, and insight into how companies are shaping their environmental policies around biosimilars.
Julie Reed Catalogues Actions Needed to Ensure Biosimilars Benefit Patients
May 29th 2022Combatting misinformation surrounding interchangeability and incentivizing biosimilars are just some of the many things that can be done to ensure patients benefit from biosimilars savings, said Julie M. Reed, the executive director of the Biosimilars Forum.
Dr Sonia Oskouei Predicts How Bevacizumab Use Will Evolve in Ophthalmology
May 22nd 2022The use of bevacizumab products for ophthalmic conditions will continue to evolve as the market grows. However, off-label usage will likely be the norm, according to Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.
Eye on Pharma: Similis Bio Launch, Biocon Biologics Sets Sights on Malaysian Biosimilar Market
May 19th 2022New biosimilars are on the way, as JSR Life Sciences launches its business division (Similis Bio) that will improve efficiency and costs related to biosimilar development and Biocon Biologics signs a contract for commercialization in Malaysia.